SciELO - Scientific Electronic Library Online

 
vol.138 número7Impacto de la apolipoproteína A5 en el riesgo cardiovascular: Modulaciones genéticas y ambientalesDisfunción miocárdica en la sepsis índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

CAIROLI, ERNESTO; ESPINOSA, GERARD  y  CERVERA, RICARD. Biological therapies in systemic lupus erythematosus. Rev. méd. Chile [online]. 2010, vol.138, n.7, pp.881-887. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872010000700014.

The immunosuppressive agents used in patients with systemic lupus erythematosus (SLE) have signifcantly improved prognosis. However, it is necessary to develop more specifc immunosuppressive treatments with less toxicity. Better understanding of the mechanisms involved in the loss of tolerance in autoimmune diseases has contributed to the development of potential new treatments called biologic therapies. The targets of these biological therapies are directed toward the B cell depletion, interference in the co-stimulation signals and the blockade of cytokines. Therapies using anti-CD20 monoclonal antibodies have shown satisfactory results especially in patients with SLE refractory to conventional treatment. The biological therapies provide encouraging results that represent a possible option in the treatment of refractory patients as well as a potential therapy in the future management of SLE.

Palabras clave : Antibodies, monoclonal; B cell activating factor; Biological therapy; Lupus erythematosus, systemic; Rituximab.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons